Control of the complement system - PubMed (original) (raw)
Review
Control of the complement system
M K Liszewski et al. Adv Immunol. 1996.
Abstract
The complement system has developed a remarkably simple but elegant manner of regulating itself. It has faced and successfully dealt with how to facilitate activation on a microbe while preventing the same on host tissue. It solved this problem primarily by creating a series of secreted and membrane-regulatory proteins that prevent two highly undesirable events: activation in the fluid phase (no target) and on host tissue (inappropriate target). Also, if not checked, even on an appropriate target, the system would go to exhaustion and have nothing left for the next microbe. Therefore, the complement enzymes have an intrinsic instability and the fluid-phase control proteins play a major role in limiting activation in time. The symmetry of the regulatory process between fluid phase and membrane inhibitors at the C4/C3 step of amplification and convertase formation as well as at the MAC steps are particularly striking features of the self/nonself discrimination system. The use of glycolipid anchored proteins on membranes to decay enzymes and block membrane insertion events is unlikely to be by chance. Finally, it is economical for the cofactor regulatory activity to produce derivatives of C3b that now specifically engage additional receptors. Likewise, C1-Inh leads to C1q remaining on the immune complex to interact with the C1q receptor. Thus the complement system is designed to allow rapid, efficient, unimpeded activation on an appropriate foreign target while regulatory proteins intervene to prevent three undesirable consequences of complement activation: excessive activation on a single target, fluid phase activation, and activation on self.
Similar articles
- Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW, Kadlec JV, Petrella EC, Bredehorst R, Vogel CW. Ollert MW, et al. Cancer Res. 1993 Feb 1;53(3):592-9. Cancer Res. 1993. PMID: 8425193 - Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship.
Holmes CH, Simpson KL. Holmes CH, et al. Baillieres Clin Obstet Gynaecol. 1992 Sep;6(3):439-60. doi: 10.1016/s0950-3552(05)80005-7. Baillieres Clin Obstet Gynaecol. 1992. PMID: 1446417 Review. - Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT, Daha MR, Strom TB, Weiler JM, Carpenter CB, Austen KF. Fearon DT, et al. Transplant Proc. 1977 Mar;9(1):729-39. Transplant Proc. 1977. PMID: 325806 Review. - The control of homologous lysis.
Lachmann PJ. Lachmann PJ. Immunol Today. 1991 Sep;12(9):312-5. doi: 10.1016/0167-5699(91)90005-E. Immunol Today. 1991. PMID: 1721817 Review. - Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
Fearon DT. Fearon DT. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71. doi: 10.1073/pnas.76.11.5867. Proc Natl Acad Sci U S A. 1979. PMID: 293688 Free PMC article.
Cited by
- Continual low-level activation of the classical complement pathway.
Manderson AP, Pickering MC, Botto M, Walport MJ, Parish CR. Manderson AP, et al. J Exp Med. 2001 Sep 17;194(6):747-56. doi: 10.1084/jem.194.6.747. J Exp Med. 2001. PMID: 11560991 Free PMC article. - What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis.
Maurer M, Dondji B, von Stebut E. Maurer M, et al. Med Microbiol Immunol. 2009 Aug;198(3):137-46. doi: 10.1007/s00430-009-0114-9. Epub 2009 Apr 25. Med Microbiol Immunol. 2009. PMID: 19396461 Review. - Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics.
Miyauchi E, Furuta T, Ohtsuki S, Tachikawa M, Uchida Y, Sabit H, Obuchi W, Baba T, Watanabe M, Terasaki T, Nakada M. Miyauchi E, et al. PLoS One. 2018 Mar 7;13(3):e0193799. doi: 10.1371/journal.pone.0193799. eCollection 2018. PLoS One. 2018. PMID: 29513714 Free PMC article. - The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.
Thurman JM, Frazer-Abel A, Holers VM. Thurman JM, et al. Arthritis Rheumatol. 2017 Nov;69(11):2102-2113. doi: 10.1002/art.40219. Epub 2017 Oct 17. Arthritis Rheumatol. 2017. PMID: 28732131 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous